Xbrane Biopharma: Still A Hidden Gem

Research Update

2022-11-03

08:15

Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report. Only a few weeks remain until the anticipated approval of Ximluci by the European Commission, bringing the Q1 2023 launch in Europe closer. 2023 will be a pivotal year for Xbrane, and the share price is likely to follow, we judge.

FE

FT

Filip Einarsson

Fredrik Thor

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.